NCT00817180

Brief Summary

This study is a preliminary study designed to determine the safety and effectiveness of HFCWO using the InCourage vest system as an airway clearance technique for the treatment of CF. The study will compare HFCWO to the most commonly used airway clearance technique in Canada, namely the Positive Expiratory Pressure technique in patients with CF over a period of one year. As this is a preliminary study, it will not be able to determine if the vest is equivelant to PEP, but will provide the information needed to plan a larger study to answer that question.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
107

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Oct 2008

Typical duration for phase_2

Geographic Reach
1 country

13 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2008

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

January 2, 2009

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 6, 2009

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2012

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2012

Completed
Last Updated

March 17, 2014

Status Verified

March 1, 2014

Enrollment Period

3.5 years

First QC Date

January 2, 2009

Last Update Submit

March 14, 2014

Conditions

Keywords

physiotherapyairway clearance techniquesPositive Expiratory Pressure Techniquehigh frequency Chest Wall Oscillationvest

Outcome Measures

Primary Outcomes (1)

  • Difference in the number of respiratory exacerbations during the 1 year study period

    1 year

Secondary Outcomes (1)

  • The time to the first respiratory exacerbation. Change in FEV1 measured as difference in the yearly mean rate of decline. Cost analysis between the two groups. Quality of life questionnaire. Patient satisfaction questionnaire and Adherence to treatment.

    1 year

Study Arms (2)

A

ACTIVE COMPARATOR

Positive Expiratory Pressure (PEP) - an airway clearance technique

Other: Positive Expiratory Pressure (PEP)

B

ACTIVE COMPARATOR

High Frequency Chest Wall Oscillation (HFCWO) also known as the 'Vest technique' - an airway clearance technique.

Other: High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System

Interventions

Physiotherapy technique for airway clearance

A

Physiotherapy technique for airway clearance.

B

Eligibility Criteria

Age6 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female 6 years of age or older at enrollment and be competent in performing spirometry.
  • Confirmed diagnosis of CF.
  • FEV1\> 45% predicted as calculated by Wang reference equations
  • Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
  • Clinically stable at enrollment with no evidence of respiratory exacerbation within a month of enrollment as assessed by the site CF Physician.
  • Willingness to adhere to prescribed treatment regimen.

You may not qualify if:

  • Diagnosis of Allergic Broncho-Pulmonary Aspergillosis, or a persistent culture for B.cepacia complex within the previous 1 year period
  • On active treatment for non Tuberculous Mycobacterium.
  • Use of intravenous antibiotics within the previous 14 days of enrollment.
  • Initiation and or change in maintenance therapy within 14 days of enrollment.
  • Use of systemic corticosteriods (1mg/kg if \< 20 kg or 20 mg of prednisone per day) within 14 days of enrollment.
  • Concurrent participation in another study that could potentially affect the present study.
  • Haemoptysis of over 20 mls on more than 2 occasions within the previous 30 days from enrollment.
  • A pneumothorax in the six months preceding the study.
  • Presence of a condition or abnormality that in the opinion of the site CF Physician would compromise the safety of the patient or the quality of the data.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

Foothills Medical Centre

Calgary, Alberta, T2N 2T9, Canada

Location

Alberta Children's Hospital

Edmonton, Alberta, T3B 2C8, Canada

Location

University of Alberta Hospitals

Edmonton, Alberta, T6G 2B7, Canada

Location

BC Children's Hospital

Vancouver, British Columbia, V6H 3V4, Canada

Location

St. Paul's Hospital

Vancouver, British Columbia, V6Z 1Y6, Canada

Location

Children's Hospital of Winnipeg

Winnipeg, Manitoba, R3A 1S1, Canada

Location

St. Clare's Mercy Hospital

St. John's, Newfoundland and Labrador, A1C 5B8, Canada

Location

Children's Hospital of Eastern Ontario

Ottawa, Ontario, K1H 8L1, Canada

Location

Ottawa General Hospital

Ottawa, Ontario, K1H 8L6, Canada

Location

The Hospital for Sick Children, Toronto

Toronto, Ontario, Canada

Location

Montreal Children's Hospital

Montreal, Quebec, H3H 1P3, Canada

Location

CHU Ste-Justine

Montreal, Quebec, H3T 1C5, Canada

Location

Centre Mere-Enfant du CHUQ

Québec, Quebec, G1V 4G2, Canada

Location

Related Publications (1)

  • McIlwaine MP, Alarie N, Davidson GF, Lands LC, Ratjen F, Milner R, Owen B, Agnew JL. Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis. Thorax. 2013 Aug;68(8):746-51. doi: 10.1136/thoraxjnl-2012-202915. Epub 2013 Feb 13.

Related Links

MeSH Terms

Conditions

Cystic Fibrosis

Interventions

Positive-Pressure RespirationChest Wall Oscillation

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesLung DiseasesRespiratory Tract DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesInfant, Newborn, Diseases

Intervention Hierarchy (Ancestors)

Respiration, ArtificialAirway ManagementTherapeuticsRespiratory Therapy

Study Officials

  • Maggie McIlwaine, Physio

    BC Children's Hospital, Vancouver

    PRINCIPAL INVESTIGATOR
  • George Davidson, MD

    BC Children's Hospital, Vancouver

    STUDY DIRECTOR
  • Candice Bjornson, MD

    Alberta Children's Hospital

    STUDY DIRECTOR
  • Clare Smith, Physio

    Alberta Children's Hospital

    STUDY DIRECTOR
  • Hans Pasterkamp, MD

    Children's Hospital of Winnipeg

    STUDY DIRECTOR
  • Linda Kraemer, Physio

    Children's Hospital of Winnipeg

    STUDY DIRECTOR
  • Felix Ratjen, MD

    The Hospital for Sick Children, Toronto

    STUDY DIRECTOR
  • Jennifer Agnew, Physio

    The Hospital for Sick Children, Toronto

    STUDY DIRECTOR
  • Larry Lands, MD

    Montreal Children's Hospital of the MUHC

    STUDY DIRECTOR
  • Nancy Alarie, Physio

    Montreal Children's Hospital of the MUHC

    STUDY DIRECTOR
  • Pearce Wilcox, MD

    St. Paul's Hospital, Vancouver

    STUDY DIRECTOR
  • Brigette Wilkins, Physio

    St. Paul's Hospital, Vancouver

    STUDY DIRECTOR
  • Sherri Katz, MD

    Children's Hospital of Eastern Ontario, Ottawa

    STUDY DIRECTOR
  • Linda Lapointe, Physio

    Children's Hospital of Eastern Ontario

    STUDY DIRECTOR
  • Shawn Aaron, MD

    The Ottawa Hospital

    STUDY DIRECTOR
  • Lynne Orser, Physio

    The Ottawa Hospital

    STUDY DIRECTOR
  • Harvey Rabin, MD

    Foothills Medical Centre, Calgary

    STUDY DIRECTOR
  • Julie Wilson, Physio

    Foothills Medical Centre, Calgary

    STUDY DIRECTOR
  • Mary Noseworthy, MD

    Janeway Children's Health & Rebab. Centre, St. John's

    STUDY DIRECTOR
  • Stephanie Spencer, Physio

    St. Clare's Mercy Hospital, St. John's

    STUDY DIRECTOR
  • Peter Zuberbuhler, MD

    University of Alberta Hospitals, Edmonton

    STUDY DIRECTOR
  • Suzanne Bergsten, Physio

    University of Alberta Hospitals, Edmonton

    STUDY DIRECTOR
  • Neil Brown, MD

    University of Alberta Hospitals, Edmonton

    STUDY DIRECTOR
  • Joyce Sharum, Physio

    University of Alberta Hospitals, Edmonton

    STUDY DIRECTOR
  • Jacques-Edouard Marcotte, MD

    CHU Ste-Justine, Montreal

    STUDY DIRECTOR
  • Nadia Marquis, Physio

    CHU Ste-Justine, Montreal

    STUDY DIRECTOR
  • Patrick Daigneault, MD

    CHUQ, Universite Laval, Quebec

    STUDY DIRECTOR
  • Christine Bouchard, Physio

    CHUL, Universite Laval, Quebec

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 2, 2009

First Posted

January 6, 2009

Study Start

October 1, 2008

Primary Completion

April 1, 2012

Study Completion

July 1, 2012

Last Updated

March 17, 2014

Record last verified: 2014-03

Locations